4.7 Article

Cognitive decline associated with pathological burden in primary age-related tauopathy

Journal

ALZHEIMERS & DEMENTIA
Volume 13, Issue 9, Pages 1048-1053

Publisher

ELSEVIER SCIENCE INC
DOI: 10.1016/j.jalz.2017.01.028

Keywords

Primary age-related tauopathy; Tau; Cognition; Clinical prognosis

Funding

  1. FOCUS Medical Student Fellowship in Women's Health - Patricia Kind, National Institutes of Health (NIH) [AG043503, AG010124, AG039510]
  2. Penn Institute on Aging
  3. Dana Foundation
  4. National Institute on Aging (NIA)/NIH [U01 AG016976]
  5. NIA [P30 AG019610, P30 AG013846, P50 AG008702, P50 AG025688, P50 AG047266, P30 AG010133, P50 AG005146, P50 AG005134, P50 AG016574, P50 AG005138, P30 AG008051, P30 AG013854, P30 AG008017, P30 AG010161]
  6. National Institute on Aging [P50 AG047366, P30 AG010129, P50 AG016573, P50 AG016570, P50 AG005131, P50AG023501, P30AG035982, P30 AG028383, P30 AG010124, P50 AG005133, P50 AG005142, P30 AG012300, P50 AG005136, P50 AG033514, P50 AG005681, P50 AG047270]

Ask authors/readers for more resources

Introduction: Primary age-related tauopathy (PART) is a neuropathological diagnosis characterized by tau neurofibrillary tangles (NFTs) in the absence of amyloid plaque pathology. Although most individuals over 50 years of age have evidence of NFTs, the clinical and cognitive consequences of PART are not known. Methods: We evaluated 226 neuropathologically confirmed PART cases from the National Alzheimer's Coordinating Center database who participated in a total of 846 longitudinal neuropsychological assessments from the Alzheimer's Disease Center program's Uniform Data Set. Mixed-effects statistical models tested whether cognitive decline was associated with Braak stage NFT burden. Results: Higher stages of NFT burden in PART, with no evidence or minimal evidence of amyloid pathology, were associated with more rapid decline on tasks involving episodic and semantic memory along with tests of processing speed and attention. Discussion: We conclude that PART has cognitive consequences that should be considered in the context of emerging tau-targeted therapies in age-associated neurodegenerative diseases. (C) 2017 the Alzheimer's Association. Published by Elsevier Inc. All rights reserved.

Authors

I am an author on this paper
Click your name to claim this paper and add it to your profile.

Reviews

Primary Rating

4.7
Not enough ratings

Secondary Ratings

Novelty
-
Significance
-
Scientific rigor
-
Rate this paper

Recommended

No Data Available
No Data Available